https://en.bharatpedia.org/w/index.php?action=history&feed=atom&title=Torrent_PharmaceuticalsTorrent Pharmaceuticals - Revision history2026-10-27T22:58:08ZRevision history for this page on the wikiMediaWiki 1.43.6https://en.bharatpedia.org/w/index.php?title=Torrent_Pharmaceuticals&diff=456618&oldid=prevWikialpha49: further fixed section per standard format and corrected details2026-03-27T23:43:42Z<p>further fixed section per standard format and corrected details</p>
<a href="//en.bharatpedia.org/w/index.php?title=Torrent_Pharmaceuticals&diff=456618&oldid=142310">Show changes</a>Wikialpha49https://en.bharatpedia.org/w/index.php?title=Torrent_Pharmaceuticals&diff=142310&oldid=prev2405:201:D002:39CC:28D4:73AC:19A5:E12A at 05:09, 24 August 20212021-08-24T05:09:30Z<p></p>
<p><b>New page</b></p><div>{{short description|Indian multinational pharmaceutical company}}<br />
{{More citations needed|date=April 2010}}<br />
{{Use dmy dates|date=November 2018}}<br />
{{Use Indian English|date=November 2018}}<br />
{{Infobox company<br />
| name = Torrent Pharmaceuticals Limited<br />
| type = [[Public company|Public]]<br />
| traded_as = {{plainlist|<br />
*{{BSE|500420}}<br />
*{{NSE|TORNTPHARM}}}}<br />
| ISIN = INE685A01028<br />
| logo = Torrent-pharmaceuticals-logo.png<br />
| foundation = {{start date and age|1959}} <br />
| location = [[Ahmedabad]], [[Gujarat]], India<br />
| founders = [[U. N. Mehta]] <br />
| key_people = [[Sudhir Mehta]], [[Samir Mehta]]<br />
| area_served = Worldwide<br />
| industry = [[Pharmaceutical industry|Pharmaceuticals]]<br />
| products = {{hlist|[[Pharmaceutical]]s |[[Generic drug]]s |[[Over-the-counter drug]]s |[[Vaccine]]s |[[Medical diagnosis|Diagnostics]] |[[Contact lens]]es |[[Veterinary medicine|Animal health]] }} <br />
| revenue = {{increase}} {{INRConvert|8060|c}} (2020)<ref name="Financials">{{cite web|url=https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/torrentpharmaceuticals/TP06|title=Torrent Pharmaceuticals Ltd. Financial Statements |website=moneycontrol.com}}</ref><br />
| operating_income = {{increase}} {{INRConvert|1637|c}} (2020)<ref name="Financials"/><br />
| net_income = {{increase}} {{INRConvert|1024|c}} (2020)<ref name="Financials"/><br />
| assets = {{increase}} {{INRConvert|14037|c}} (2020)<ref name="Financials"/><br />
| equity = {{increase}} {{INRConvert|4738|c}} (2020)<ref name="Financials"/><br />
| num_employees = 12,881 (2020)<ref name="Financials"/> <br />
| parent = [[Torrent Group]] <br />
| homepage = [http://www.torrentpharma.com/ www.torrentpharma.com]<br />
}}<br />
<br />
'''Torrent Pharmaceuticals Ltd''' is an Indian [[multinational corporation|multinational]] [[pharmaceutical company]], owned by [[Torrent Group]] and headquartered in [[Ahmedabad]]. It was promoted by [[U. N. Mehta]], initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.<br />
<br />
Torrent Pharmaceuticals operates in more than 40 countries with over 2000 product registrations globally. Torrent Pharma is active in the therapeutic areas of Cardiovascular (CV), central nervous system (CNS), gastro-intestinal, diabetology, anti-infective and pain management segments. It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments.<br />
Drug firm Torrent Pharmaceuticals on 23 July 2019 reported a 32.51 percent rise in its consolidated net profit to Rs 216 crore for the quarter ended 30 June, mainly on account of robust sales in most geographies.<ref>{{cite news|url=https://business.medicaldialogues.in/torrent-pharma-q1-net-profit-up-33-percent-to-rs-216-crore/|title= Torrent Pharma Q1 net profit up 33 percent to Rs 216 crore<br />
|date=23 July 2019|work=Medical Dialogues}}</ref><br />
<br />
== Subsidiaries ==<br />
It has 7 fully owned subsidiaries:<br />
# Heumann Pharma GmbH & Co Generica KG, [[Germany]]<br />
# Torrent Pharma GmbH, [[Germany]]<br />
# Torrent do Brasil Ltda., [[Brazil]]<br />
# ZAO Torrent Pharma, [[Russia]]<br />
# Torrent Pharma Inc., [[United States]]<br />
# Torrent Pharma Philippines Inc., [[Philippines]]<br />
# Torrent Pharma Canada Inc., [[Canada]]<br />
# Torrent Pharma UK United Kingdom<br />
<br />
Torrent Pharmaceuticals acquired Heumann GmbH, a [[Pfizer]] company, in 2005.<br />
<br />
==Operations==<br />
The company's key areas are Formulations, API, Drug Discovery, Marketing and Sales of Drugs. Its operations locations are:<br />
* Manufacturing plant at Dahej, [[Gujarat]] <br />
* Manufacturing plant<ref>{{Cite web|url=https://www.vccircle.com/torrent-pharma-acquires-us-based-bio-pharm/|title=Torrent Pharma acquires US-based Bio-Pharm|last=Sunkara|first=Keshav|date=19 January 2018|website=VCCIRCLE|access-date=20 July 2019}}</ref> at Pithampur,<ref>{{Cite news|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/torrent-pharma-gets-establishment-nod-from-usfda/articleshow/51453971.cms|title=Torrent Pharma gets establishment nod from USFDA|last=PTI|date=18 March 2016|work=The Economic Times|access-date=20 July 2019}}</ref> [[Madhya Pradesh]]<br />
* Manufacturing plant at Indrad, Mehsana, [[Gujarat]]<br />
* Manufacturing plant at Baddi, [[Himachal Pradesh]]<br />
* 3 Manufacturing plant at Rang-Po,(Sikkim)<br />
* Research Centre, [[Ahmedabad]]-[[Gandhinagar]] region, [[Gujarat]]<br />
* Corporate Office, beside sales India, off. Ashram Road, [Ahmedabad]- [[Gujarat]]<br />
* Manufacturing plant at Visakhapatnam (Andhra Pradesh)<br />
<br />
==Recalls==<br />
In 2018, Torrent Pharmaceuticals recalled tablets containing [[valsartan]]<ref name=ucm617821>{{cite web |title=Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets |url=https://www.fda.gov/Safety/Recalls/ucm617821.htm |year=2018 |quote=<small>Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.</small>}}</ref><ref name=ucm613916>{{cite web |url=https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm |title=FDA updates on valsartan recalls |year=2018}}</ref> and [[losartan]]<ref name=ucm628966>{{cite web |title=Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP |url=https://www.fda.gov/Safety/Recalls/ucm628966.htm |year=2018 |quote=<small>Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.</small>}}</ref> due to the detection of [[N-nitrosodimethylamine|''N''-nitrosodimethylamine]] (NDMA) and [[N-Nitrosodiethylamine|''N''-nitrosodiethylamine]] (NDEA) respectively which are probable human carcinogens.<br />
<br />
In September 2019, the FDA issued notice of a sixth [[product recall]] of losartan by Torrent Pharmaceuticals when certain batches of losartan contained the contaminant, N-methylnitrosobutyric acid (NMBA), above acceptable daily intake levels determined by the FDA.<ref name="fda9-23-19">{{cite web |title=Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP |url=https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0 |publisher=US Food and Drug Administration |accessdate=23 September 2019 |date=23 September 2019}}</ref><br />
<br />
==References==<br />
{{reflist|2}}<br />
<br />
==External links==<br />
*{{Official}}<br />
<br />
{{Torrent Group}}<br />
{{Nifty 200 companies}}<br />
<br />
[[Category:Companies based in Ahmedabad]]<br />
[[Category:Pharmaceutical companies of India]]<br />
[[Category:Pharmaceutical companies established in 1959]]<br />
[[Category:Indian brands]]<br />
[[Category:Torrent Group]]<br />
[[Category:1959 establishments in Bombay State]]<br />
[[Category:Indian companies established in 1959]]<br />
[[Category:Companies listed on the National Stock Exchange of India]]<br />
[[Category:Companies listed on the Bombay Stock Exchange]]</div>2405:201:D002:39CC:28D4:73AC:19A5:E12A